Elanco Animal Health is delighted to announce that Coliprotec® F4/F18 will be available in the UK and Ireland from May 2017.
Coliprotec® F4/F18 is the first single dose oral vaccine intended for active immunization of pigs against enterotoxigenic F4- and F18-positive Escherichia coli, two significant agents of post-weaning diarrhea (PWD), a major cause of economic loss for swine producers.
Through proactive immunization, Coliprotec® F4/F18 can contribute to herd health and performance by reducing both the incidence of moderate to severe PWD and faecal shedding of enterotoxigenic F4- and F18-positive Escherichia coli from infected pigs.
Ciara O’Neill, Elanco’s UK and Ireland Technical Consultant, said: “Coliprotec F4/F18 is a sustainable and innovative solution to the age-old problem of post-weaning scours. Vets and farmers can have confidence in this new addition to their PWD toolbox, which will limit the impact of ETEC E.coli at such an important stage in the pig’s life. Coliprotec F4/F18 has the potential to change current practices on farm, and could reduce the need for antibiotics post-weaning”.
Gaynor Hillier, Elanco’s Affiliate Director for the UK and Ireland, added: “As a major breakthrough in the fight against post-weaning diarrhea in pigs, Coliprotec® F4/F18 is a significant addition to our range of vaccines in the UK and Ireland. We see this as a further opportunity to deliver innovation and value to our customers, offering them a new vaccine to protect piglets against PWD.”
Coliprotec® F4/F18 has been developed by Prevtec Microbia and will be distributed by Elanco Animal Health in the European Union.
- Post-weaning diarrhoea (PWD) is caused by enterotoxigenic F4- and F18-Escherichia coli.
- Coliprotec® F4/F18 is an oral vaccine used for active immunization of pigs from 18 days of age against enterotoxigenic F4-positive and F18-positive Escherichia coli in order to reduce the incidence of moderate to severe post-weaning diarrhea infected pigs and reduce the faecal shedding of enterotoxigenic F4-positive and F18-positive E. coli from infected pigs.
- Each dose of vaccine contains 1.3 x 108 to 9.0 x 108 CFU of live non-pathogenic Escherichia coli O8:K87 (F4ac) and 2.8 x 108 to 3.0 x 109 CFU of live non-pathogenic Escherichia coli O141:K94 (F18ac). Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contraindications. Legal category POM-V
For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco Animal Health (the animal health division of Eli Lilly and Company Limited), Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL. For further information consult the product SPC.
Use medicines responsibly www.noah.co.uk/responsible.
COLIPROTEC ® is a registered trademark of Prevtec Microbia Inc, used under license by Elanco, a division of Eli Lilly.
ElancoTM and the Diagonal BarTM are registered trademarks owned by or licensed to Eli Lilly and Company, its affiliates or subsidiaries.
©2017 Eli Lilly and Company.